Both targets mutate a lot AFAIK so I agree This is a 10k patient phase 2. Wow. They will need to test the drug against different VOCs to assess if they really do have greater breadth of coverage
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.